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Objectives: To investigate whether Helicobacter spp. infection and the cagA of H. pylori are
associated with hepatobiliary pathology, specifically biliary inflammation, cell proliferation and
cholangiocarcinoma (CCA).
Methods: Helicobacter species including H. pylori, H. bilis and H. hepaticus were detected in the speci-
mens using the polymerase chain reaction (PCR). Biliary inflammation of the liver and gallbladders was
semi-quantitatively graded on hematoxylin and eosin (H&E)-stained slides. Biliary proliferation was
evaluated by immunohistochemistry using the Ki-67-labelling index.
Results: Helicobacter pylori was found in 66.7%, 41.5% and 25.0% of the patients in the CCA,
cholelithiasis and control groups (P < 0.05), respectively. By comparison, H. bilis was found in 14.9% and
9.4% of the patients with CCA and cholelithiasis, respectively (P > 0.05), and was absent in the control
group. The cagA gene of H. pylori was detected in 36.2% and 9.1% of the patients with CCA and
cholelithiasis, respectively (P < 0.05). Among patients with CCA, cell inflammation and proliferation in the
liver and gallbladder were significantly higher among those DNA H. pylori positive than negative.
Conclusions: The present findings suggest that H. pylori, especially the cagA-positive strains, may be
involved in the pathogenesis of hepatobiliary diseases, especially CCA through enhanced biliary cell
inflammation and proliferation.
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Introduction
Cholangiocarcinoma (CCA), a subtype of primary liver cancer
arising from bile duct epithelial cells, is a rare malignant tumour
worldwide but it is highly prevalent in Asian countries, particu-
larly in Thailand.1 Both epidemiological and experimental evi-
dence have implicated the liver flukes, Opisthorchis viverrini and
Clonorchis sinensis, as important carcinogenic agents in the devel-
opment of CCA.2 However, only a small proportion of liver fluke-
infected patients develop CCA.3 Other factors, such as bacterial
infection in the hepatobiliary tract, may therefore synergistically
trigger tumour development. In this regard, it has been postulated
that Helicobacter spp. may be involved in the development of
CCA.4
Helicobacter spp. (includingH. pylori,H. hepaticus andH. bilis)
have been found in the bile,5 gallbladder6 and liver tissue7 of
patients with hepatobiliary diseases. Helicobacter pylori is a well-
recognized causative factor of gastrointestinal diseases, and has
been strongly linked to the development of gastric adenocarci-
noma.8 Previous experimental studies showed that H. bilis and
H. hepaticus were found in the bile and hepatobiliary tissues of
patients with biliary tract diseases using a polymerase chain
reaction (PCR) assay.5,9 Helicobacter pylori has frequently been
detected in patients with liver carcinoma and CCA;7,10–12 however,
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there were only small numbers of CCA cases in these studies and
the results are still under debate.13 In order to increase the under-
standing of the association and pathogenesis of Helicobacter spp.
infection and the development of hepatobiliary disease including
CCA, we performed a systemic investigation of the Helicobacter
infection and its associated pathology in a large number of benign
and malignant hepatobiliary diseases and normal controls.
Materials and methods
Patients and specimens
Bile samples were collected from 140 patients including 87 with
CCA (the malignant group) and 53 with cholelithiasis (the benign
group) who underwent surgery at SrinagarindHospital, Faculty of
Medicine, Khon Kaen University. From the 87 patients with CCA,
liver (n = 21) and gallbladder tissues (n = 44) were additionally
collected. From the 53 patients with cholelithiasis, an additional
35 gallbladders and 16 gallstones were collected. The bile samples
from the normal control group were collected from 16 autopsied
cases. Patients with gastrointestinal diseases and hepatitis virus
infection were excluded. The human ethics committee at our
institution reviewed and approved the present study (HE 450525).
All of the patients provided informed consent before participating
in the study.
DNA extraction
Approximately 50 mg each of gallbladder tissue, liver tissue (can-
cerous and non-cancerous) and gallstone were transferred to
respective sterile normal saline solution under cold conditions.
Each of the specimens was homogenized with a glass tissue
grinder in 500 ml of lysis buffer. As for the bile specimens, 2 ml of
bile sample were diluted with 1 volume of sterile phosphate-
buffered saline (PBS). After centrifugation at 13 000 ¥ g, the bile
pellet was re-suspended in 500 ml of lysis buffer.
DNA was extracted using a genomic DNA purification kit
(Puregene; Gentra System Inc., Minneapolis, MN, USA), accord-
ing to the manufacturer’s instructions. Briefly, the bile pellet – or
ground sample in lysis buffer – was treated with 4 ml of protein-
aseK (20 mg/ml) for 3 h at 55°C. The lysate was incubated at 98°C
for 10 min; then 4 ml of RNaseA (25 mg/ml) was added to the cell
lysate and incubated at 37°C for 1 h. Then, 300 ml of protein
precipitation solution was added and centrifuged at 13 000 ¥ g for
5 min. The supernatant was collected and precipitated by 2
volumes of absolute ethanol and centrifuged at 13 000 ¥ g for
5 min. After washing the DNA pellet with 70% ethanol, the DNA
was dried and suspended in TE buffer and stored at -20°C until
needed.
As for the bile samples, after precipitation by two volumes of
absolute ethanol, the DNA pellet was purified using a column and
washed twice with a washing buffer. Finally, the DNA was eluted
with 50 ml of elution buffer. The DNA was stored at -20°C until
needed.
Detection of Helicobacter spp., H. pylori, H. bilis,
H. hepaticus and cagA by PCR assay
Primer sequences for the detection of Helicobacter spp.; H. pylori,
H. bilis, H. hepaticus and cagA gene were designed as previously
described10,14–16 with slight modifications (Table 1).
All reactions were carried out in a 50-ml solution containing
500 ng from the hepatobiliary specimens. The reaction mixture
contained 1¥ PCR buffer (RBC; Bioscience, Taipei, Taiwan),
0.2 mM dNTP, 1.5 mMMgCl2+, 0.2 mMprimers and 1.25 U of Taq
DNA polymerase (RBC, Bioscience, Taipei, Taiwan). PCR was per-
formed in an automated thermocycle (GeneAmp, PCR 2400;
PerkinElmer, Waltham MA, USA). The amplified product was
identified by electrophoresis in 1.5% agarose gel. The DNA was
stained with ethidium bromide and visualized under a UV
illuminator.
Bacterial culture
For the Helicobacter spp. cultivation, the ground tissue and 100 ml
of bile from each respective sample was inoculated onto the Belo
Horizonte medium and Columbia blood agar supplemented with
10% human whole blood cell, 10 mg/ml of vancomycin, 5 mg/ml
of trimethoprim, 5 mg/ml of cefsulodin and 5 mg/ml of ampho-
tericin B. The media was incubated under microaerophilic
conditions at 37°C for up to 2 weeks. For the other bacterial
cultivations, 100 ml of ground tissue or bile sample was inoculated
onto a blood agar base and MacConkey agar. The plates were
incubated at 37°C for 24–48 h. The colonies that grew on the
plates were identified using biochemical tests.17
Biliary inflammation
Evaluation of inflammation was performed according to Fukuda
et al.5 The paraffin-embedded tissues of the gallbladder and
liver tissue were cut onto glass slides coated with 5-
aminoprophyltriethoxy saline and stained with hematoxylin and
eosin (H&E). Inflammatory cell infiltration along the portal triads
and gallbladder mucosa were semi-quantitatively graded:
0 = unremarkable (0–25% of mononuclear cell infiltration),
1 = mild chronic inflammation (25–50% of mononuclear infiltra-
tion), 2 = moderate chronic inflammation (50–75% of mono-
nuclear cell infiltration) and 3 = severe chronic inflammation
with lymphoid aggregation (>75% of mononuclear cell infiltra-
tion). All tissue sections were examined in a blinded fashion
without knowledge of the clinical data or PCR results at the time
of the assessment.
Biliary proliferation
Biliary cell proliferation was determined by immunohistochemis-
try using Ki-67. Tissue sections were incubated overnight with
mouse monoclonal anti-Ki-67 (Dako, Glostrup Denmark,
Denmark) at dilutions of 1 : 100 at 4°C. After incubation with the
primary antibody, the tissue section was incubated with goat anti-
mouse conjugated with peroxidase (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). The reaction was visualized using diami-
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nobenzidine as a substrate. The Ki-67 protein expression was ana-
lyzed by calculation of the percentage of Ki-67 labelled biliary
cells, with respect to the total number of biliary epithelial cells
(labelling index, LI).
Statistical analysis
The c2 or Fisher’s exact test was used for statistical analysis of the
H. pylori infection, virulence genes and patient groups. Associa-
tions between biliary inflammation, Ki-67-LI and the disease
groups were analyzed using the Student’s t-test. Differences at
P < 0.05 were considered statistically significant.
Results
Detection of Helicobacter spp. (H. pylori, H. bilis and
H. hepaticus) by PCR
Helicobacter spp. was detected in the bile samples of CCA patients
(71.3%) significantly more often than in patients with cholelithi-
asis (47.2%) or the control group (25%). The total number of
H. pylori found in the CCA patients (66.7%) was significantly
greater than in patients with cholelithiasis (41.5%) or the control
group (25.0%). While the respective total number of H. bilis
found in patients with CCA and cholelithiasis was 14.9% and
9.4%, none was found in the control group. Similarly, no PCR
product from H. hepaticus was found in either the malignant or
the benign group.
Each species of Helicobacter was analyzed. We found that
H. pylori infection alone was detected in significantly more CCA
patients (58.6%) than in patients with cholelithiasis (22.6%) or
the control group (25%) (Table 2). By comparison, H. bilis infec-
tion alone was detected in 3.4% of patients with CCA and 5.7%
with cholelithiasis (no significant difference between groups). A
mixed infection of H. pylori and H. bilis was detected in 8% and
1.9% of CCA and cholelithiasis, respectively (Table 2).
In order to confirm that the major Helicobacter spp. found was
H. pylori, we performed DNA sequencing analysis for 16srRNA
Helicobacter spp. The results showed that the amplicons, which
were randomly sequenced, were at least 98% similar to the 16S
rRNA gene of H. pylori (GeneBank accession number CP001680.1
and AY364440.1).
For other hepatobiliary specimens, the gallbladder, liver tissues
and gallstone were also tested for Helicobacter spp. The result
showed that the H. pylori was detected significantly more fre-
quently in the gallbladder of the malignant group than in the
benign group (P < 0.05). In addition,H. pylori was detected in the
liver tissues and gallstones of patients with CCA and cholelithiasis,
respectively. The presence of H. bilis was also detected but the
number was lower than H. pylori in both the malignant and
benign group (data not shown).
Table 1 Primer sequences and PCR conditions for amplification of Helicobacter spp.
Gene specific for Genes Primer sequences PCR condition PCR size Ref.
Helicobacter spp. 16S rRNA
(nested PCR)
OF-ATTAGTGGCGCACGGGTGAGTAA 94°C 30 s, 55°C 30 s, 72°C
1.5 min (35 cycle)
1300 10
OR-TTTAGCATCCCGACTTAAGGC
IF-GAACCTTACCTAGGCTTGACATTG 94°C 30 s, 60°C 30 s, 72°C
30 s (35 cycle)
480
IR-GGTGAGTACAAGACCCGGGAA
H. pylori ureA
(nested PCR)
OF-GCTAATGGTAAATTAGTTCCTGG 94°C 30 s, 62°C 30 s, 72°C
30 s (40 cycle)
411 14
OR-CTCCTTAATTGTTTTTACATAGTTG
IF-AGTTCCTGGTGAGTTGTTCTTAA 94°C 30 s, 59°C 30 s, 72°C
30 s (40 cycle)
350
IR-AACCACGCTCTTTAGCTCTGTC
H. pylori cagA
(nested PCR)
OF-AGACAACTTGAGCGAGAAAG 94°C 30 s, 55°C 30 s, 72°C
30 s (40 cycle)
320 15
OR-TATTGGGATTCTTGGAGGGG
OF-AGACAACTTGAGCGAGAAAG 94°C 30 s, 57°C 30 s, 72°C
30 s (40 cycle)
307
IR-GGAGGCGTTGGTGTATTTGA
H. bilis 16S rRNA
(nested PCR)
OF-CTATGACGGGTATOCGGC 98°C 10 s, 55°C 30 s, 72°C
1 min (35 cycle)
718 16
OR-CTCACGACACGAGCTGAC
IF-CAGAACTGCATTTGAAACTAC 98°C 10 s, 55°C 30 s, 72°C
30 s (35 cycle)
418
IR-AAGCTCTGGCAAGCCAGC
H. hepaticus 16S rRNA
(nested PCR)
OF-CTATGACGGGTATOCGGC 98°C 10 s, 55°C 30 s, 72°C
1 min (35 cycle)
718 16
OR-CTCACGACACGAGCTGAC
IF-GAAACTGTTACTCTG 98°C 10 s, 55°C 30 s, 72°C
30 s (35 cycle)
405
IR-TCAAGCTCCCCGAAGGG
PCR, polymerase chain reaction.
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Detection of H. pylori cagA gene by PCR
All of theH. pylori PCR positive samples were further analyzed for
the presence of the cagA gene. The cagA gene was detected in
36.2% and 9.1% of the CCA and cholelithiasis patients, respec-
tively. The difference between the two groups was statistically
significant (P < 0.05), and no PCR positive cagA gene was found
in the control group (Table 3).
Bacterial culture
After prolonged incubation of up to 2 weeks under microaero-
philic conditions, no Helicobacter spp. from the hepatobiliary
specimens were grown. The other bacteria found included
Escherichia coli, Klebsiella spp., Acinetobacter anitratum, Citro-
bacter freundii, Enterobacter spp., Pseudomonas aeruginosa and
Staphylococcus aureus. In patients with cholelithiasis, we found
that the types and numbers of other bacteria were significantly
higher than in the patients with CCA or in the control group
(Table 2).
Biliary inflammation
In the liver and gallbladder tissues of CCA patients, the average
inflammatory grade for H. pylori-DNA-positive tissues was sig-
nificantly higher than for patients with H. pylori-DNA-negative
tissues: In the latter cases the inflammatory grade was similar to
the gallbladder tissues of patients with cholelithiasis (Table 4).
When we evaluated the inflammatory grade of non-infected
tissues and H. bilis-PCR-positive tissue, the result was not signifi-
cantly different for either the patients with CCA or cholelithiasis.
In amixed infection ofH. pylori andH. bilis in the liver tissues, the
grade of inflammation was significantly higher than in non-
infected liver tissues (Table 4).
Furthermore, we found that gallbladder tissues of patients with
cholelithiasis infected with other bacteria (or with a multiple
infection of Helicobacter spp. and other bacteria) showed a signifi-
cantly higher inflammatory grade than that of the non-infected
gallbladder (P < 0.05). Biliary inflammation determined by H&E
staining is presented in Figs 1a, c and 2a, c.
Biliary proliferation
The liver and gallbladder tissues of CCA patients had a signifi-
cantly higher average Ki-67-LI in the H. pylori-PCR-positive
tissues than in the non-infected tissues. By comparison, among
the average Ki-67-LI in H. bilis-PCR-positive tissues and non-
infected tissues was not significantly different (Table 5). Interest-
ingly, CCA patients with a mixed infection (of H. pylori- and
H. bilis-PCR-positive) showed a significantly higher level of
Ki-67-LI than non-infected tissues in either the liver or gallblad-
der tissues. By contrast, there was no significant difference in the
average Ki-67-LI between infections and non-infections in the
gallbladder tissues of patients with cholelithiasis. The biliary pro-
liferation as determined by immunohistochemistry of Ki-67 is
presented in Figs 1b, d and 2b, d.
Discussion
The association between Helicobacter spp. infection and hepato-
biliary diseases has been reported but its roles in the pathogenesis
are still under debate.9,10,13 The present study demonstrates a
significantly higher frequency of Helicobacter spp., especially
H. pylori in the bile from CCA patients than in those with
cholelithiasis and the controls, as reported in patients with hepa-
tocellular carcinoma and CCA.7,12,13 This suggests that H. pylori
infection may be associated with the severity of hepatobiliary
diseases. Chronic cholestasis is one of the key predisposing factors
Table 2 Helicobacter spp. and other bacteria detected in bile samples of hepatobiliary diseases
Diseases Number of Helicobacter positive (%) No. of other
bacteriab
positive (%)
No. of
bacterial
negative (%)
H. pylori H. bilis H. pylori
and H. bilis
Helicobacter spp.a
and other bacteria
Total No. of
Helicobacter spp.
CCA (n = 87) 48*† (58.6) 3 (3.4) 7 (8.0) 4 (4.6) 62*†(71.3) 3 (3.4) 22 (25.3)
Cholelithiasis (n = 53) 12 (22.6) 3 (5.7) 1 (1.9) 9‡ (17.0) 25 (47.2) 12‡§ (22.6) 16 (30.2)
Control (n = 16) 4 (25.0) 0 (0) 0 (0) 0 (0) 4 (25.0) 1 (6.25) 10 (62.5)
*Statistical significance between CCA and cholelithiasis (P < 0.05).
†Statistical significance between CCA and control (P < 0.05).
‡Statistical significance between cholelithiasis and CCA (P < 0.05).
§Statistical significance between cholelithiasis and control (P < 0.05).
aHelicobacter spp. such as H. pylori and/or H. bilis.
bOther bacteria was found in bile samples, gallbladder tissues and stones samples, but was not found in liver tissues.
CCA, cholangiocarcinoma.
Table 3 Helicobacter pylori cagA positive in bile samples of hepato-
biliary diseases
Diseases Total No. (%) of H. pylori
PCR positivea
No. (%)of cagA
gene positive
CCA (n = 87) 58*† (66.7) 21*† (36.2)
Cholelithiasis (n = 53) 22 (41.5) 2 (9.1)
Control (n = 16) 4 (25.0) 0 (0)
*Statistical significance between CCA and cholelithiasis (P < 0.05).
†Statistical significance between CCA and control (P < 0.05).
aTotal number of H. pylori PCR positive was H. pylori infection alone and
mixed infection of H. pylori with H. bilis or other bacteria.
CCA, cholangiocarcinoma.
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to the development of CCA.18 Interestingly, although, cholestasis
is commonly found in bile duct obstruction caused by CCA but it
is not common in cholelithiasis.19 Previous studies have shown
that chronic cholestasis can induce lowering of the bile pH,20
creating conditions that favour H. pylori survival.21 Therefore, the
present study suggests that H. pylori can survive in the bile and
can be detected more in patients with CCA than those with
cholelithiasis and control subjects.
We found that the H. pylori was the predominant Helicobacter
species in the present study which agrees with previous
reports.22,23 Additionally, we found very few H. bilis in hepatobil-
iary specimens and no significant difference between H. bilis and
the disease groups suggesting H. bilis might play a minor role in
the pathogenesis of CCA. Our results agree with Huang and col-
leagues who reported thatH. pylori was only found in liver tissues
of hepatocellular carcinoma patients but was undetectable in the
control group, according to PCR and DNA sequencing.7 The
present findings, however, disagree with Fukuda et al. who showed
that H. bilis was frequently found in hepatobiliary cancer patients
in Japan, whereas H. pylori was found in small numbers.5 This
may be explained by the variation in Helicobacter spp. across
regions.22
Table 4 Evaluation of inflammation in liver and gallbladder tissues infected with Helicobacter pylori, H. bilis or other bacteria compared with
non-infected tissues
Diseases Tissues
collected
Average of inflammatory grade
Non-infection H. pylori+ H. bilis+ H. pylori and
H. bilis+
Other
bacteria+
Helicobacter
spp. and other
bacteria+
CCA Liver (n = 21) 1.17  0.41
(n = 6)
2.33  0.87*
(n = 9)
1.00 (n = 1) 2.40  0.89*
(n = 5)
ND ND
Gallbladder
(n = 44)
1.00  0.67
(n = 10)
2.20  0.77*
(n = 17)
1.00  1.00
(n = 3)
1.86  1.35
(n = 7)
1.00  0.58
(n = 2)
1.60  0.55
(n = 5)
Cholelithiasis Gallbladder
(n = 35)
1.13  0.83
(n = 15)
2.40  0.55*
(n = 5)
1.67  1.53
(n = 3)
2.00 (n = 1) 2.20  0.84*
(n = 5)
2.17  0.75*
(n = 6)
*P-value < 0.05 was considered a statistically significant difference between the non-infected and infected tissues.
ND, not determined (other bacteria were not found in liver tissues).
Figure 1 Evaluation of biliary inflammation by hematoxylin and eosin (H&E) staining and proliferation by immunohistochemistry staining with
Helicobacter pylori-PCR-positive and -negative in liver tissues (200¥ magnification). (a) Severe chronic inflammation of the bile duct in
H. pylori PCR-positive liver tissue. (b) High score of average Ki-67-LI of the bile duct in H. pylori-PCR-positive liver tissue. (c) Low grade
inflammation (unremarkable) of bile duct in H. pylori-PCR-negative liver tissue. (d) Low score of Ki-67-LI of the bile duct in H. pylori-PCR-
negative liver tissue
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In the present study, the DNA of the H. pylori cagA-positive
strains was detected more frequently among patients with CCA
than patients with cholelithiasis and was undetectable in the
control group. This is important because the cagA gene is an
important virulence gene in the H. pylori strain, which is known
to induce severe inflammation associated with gastric cancer.24
Based on our previous finding in vitro25 and this present study, we
suggest thatH. pylori-cagA-positive strains may be associated with
the carcinogenesis of CCA.
It is generally accepted that there is a relationship between
chronic inflammation of the stomach caused by H. pylori and
gastric carcinogenesis.26 Chronic inflammation is a major cause of
oxidative DNA damage by stimulation of NO production, leading
to a high risk of cancer development.27 In the present study,
patients with CCA and H. pylori-PCR-positive liver tissue pre-
sented with a significantly higher inflammatory grade at the portal
zone around the bile ducts than patients with a non-infected liver.
Similarly, the gallbladder mucosa in both malignant and benign
groups exhibited a statistically significant, higher level of mono-
nuclear cell infiltration in the H. pylori-PCR-positive samples
than the negative ones. Moreover, we found that co-infection of
H. pylori with other bacteria resulted in significantly more aggres-
sive inflammation (i.e. severe chronic inflammation) in the gall-
bladder mucosa of the cholelithiasis patients than in those with
Figure 2 Evaluation of biliary cell inflammation by hematoxylin and eosin (H&E) staining and proliferation by immunohistochemistry staining
with Helicobacter pylori-PCR-positive and -negative gallbladder tissues (200¥ magnification). (a) Severe chronic inflammation of H. pylori-
PCR-positive gallbladder tissue. (b) High score of average Ki-67-LI of H. pylori-PCR-positive gallbladder tissue. (c) Mild chronic inflammation
of H. pylori-PCR-negative gallbladder tissue. (d) Low score of Ki-67-LI of H. pylori-PCR-negative gallbladder tissue
Table 5 Evaluation cell proliferation in liver and gallbladder tissues infected with Helicobacter pylori or H. bilis compared with non-infected
tissues
Diseases Tissues
collected
Average of the Ki-67 labelling index
Non-infection H. pylori+ H. bilis+ H. pylori and
H. bilis+
Other
bacteria+
Helicobacter
spp. and other
bacteria+
CCA Liver (n = 21) 4.50  3.62
(n = 6)
13.44  9.15*
(n = 9)
5.00 (n = 1) 14.83  10.85*
(n = 5)
ND ND
Gallbladder
(n = 44)
5.50  3.95
(n = 10)
14.25  10.24*
(n = 17)
1.33  2.31
(n = 3)
14.71  12.27
(n = 7)
5.00  7.07
(n = 2)
6.60  8.10
(n = 5)
Cholelithiasis Gallbladder
(n = 35)
9.73  13.57
(n = 15)
12.80  14.18
(n = 5)
2.67  2.52
(n = 3)
5.00 (n = 1) 2.00  2.12
(n = 5)
10.33  6.59
(n = 6)
*P-value < 0.05 was considered a statistically significant difference between the non-infected and infected tissues.
ND, not determined (other bacteria was not found in liver tissues).
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CCA, indicating multiple bacterial infections may be associated
with the progression of gallstone formation in patients with
cholelithiasis.
Ki-67 has been used for the determination of cellular prolifera-
tive activity.28 In inflammation, several inflammatory cytokines
can induce cell proliferation, oxidative DNA damage and sur-
vival.29 In patients with CCA, a high level of inflammation at the
periportal area and gallbladder mucosa parallels a significantly
higher cell proliferative index in the H. pylori-PCR-positive
samples compared with the negative ones. This suggests that
H. pylori may have a role in the development of bile duct cancer
through the induction of cell inflammation and biliary cell pro-
liferation. This result agrees with our previous in vitro study25 and
Fukuda et al. who demonstrated that the proliferating cell nuclear
antigen labelling index (PCNA-LI) in the biliary epithelium of
Helicobacter DNA-positive patients was significantly higher than
in Helicobacter-DNA-negative ones.5
As with a previous report on an animal model, a very low level
of apoptotic cells was detected (by TUNEL assay) compared with
marked proliferation (by PCNA) in H. pylori-infected mouse liv-
ers.30 We also studied apoptosis in both liver and gallbladder
tissues using caspase-3-LI and very few apoptotic biliary cells were
detected (Data not shown). Similar to our previous in vitro report,
a low number of H. pylori stimulated biliary cell proliferation
rather than apoptosis.25
Although a few previous studies have reported on the detection
ofHelicobacter spp.orH. pylori-like spiral bacteria in hepatobiliary
samples,7,31 all were not proven by bacterial cultivation.7,32 Simi-
larly, we were unable to detect Helicobacter spp. in hepatobiliary
tissues by cultivation or immunohistochemical staining (data not
shown) aswithprevious reports.5,7,33 The inability to detect these by
cultivation may be as a result of (i) the small number of these
bacteria in hepatobiliary specimens7 and/or (ii) the unfavourable
environment in the biliary tract which may cause transformation
ofHelicobacter into its non-culturable coccoid form.34,35A previous
study showed that the coccoid form of H. pylori has persistent
urease activity, so it is able to adhere to the epithelial cell line and
this persistence caused disease in mice; suggesting that the coccoid
formofH. pylori possesses some pathogenicity.36 Studies in animal
models, however, showed that H. pylori promoted hepatic fibrosis
and was involved in the development of hepatocellular carci-
noma.30,33 On comparing our previous findings in vitro25 with the
present study, we suggest that even although there may be a very
small number of H. pylori in the hepatobiliary tract, they still play
a role in the development of CCA.
In addition, we observed that Enterobacteriaceae was the most
frequently found family, which agrees with other reports.37 Other
bacteria were found most often in patients with benign hepato-
biliary disease rather than in those with malignancies, suggesting
a possible role of other bacteria in the pathogenesis of cholelithi-
asis. These results indicate that H. pylorimay have a potential role
in hepatobiliary diseases greater than other bacteria, particularly
in CCA.
In conclusion, we investigated the presence of Helicobacter spp.
especially H. pylori with a concurrent pathological study on
biliary inflammation and proliferation. The results suggest that
H. pylori and cagA may be involved in the development of CCA.
Thus, the eradication of Helicobacter spp., and in particular
H. pylori, may be useful for the treatment of CCA. Notwithstand-
ing, it is possible that the high frequency of Helicobacter infection
among CCA patients may result from cholestasis.19,20,38 In future
studies, therefore, the cultivation of Helicobacter spp. from hepa-
tobiliary samples should be improved and animal models to
clarify the pathogenesis of Helicobacter spp. in the hepatobiliary
diseases should be studied in depth.
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